We are a team with extensive experience in drug development from the pharmaceutical industry, focusing on discovery and development of novel small molecules.
We design and develop new organ-restricted chemical entities that addresses unmet medical needs in fibrosis and cancer.
read more
Our focus is to design novel chemical entities that modulate well validated targets in fibrosis and cancer.
Our strategy involves the development of organ-restricted compounds to maximize benefit/risk in patients.
Our aim is the treatment of fibrosis and cancer through TGF-β inhibition, a well validated target considered a key regulator of fibrosis development and immunosuppression.
Español
Galego